What is Prostate Volume?
Prostate volume is the three-dimensional measurement of the prostate gland, expressed in milliliters (mL) or cubic centimeters (cc). The prostate is a walnut-sized gland located below the bladder in males, surrounding the urethra. Its primary function is to produce the fluid component of semen. In healthy young men, the prostate typically measures between 15 and 20 mL, weighing approximately 20 grams.
As men age, the prostate naturally enlarges, a condition known as Benign Prostatic Hyperplasia (BPH). This growth is driven by hormonal changes, particularly the accumulation of dihydrotestosterone (DHT) within the gland. By age 60, more than 50% of men have histological evidence of BPH, and by age 85, this figure rises to approximately 90%. Not all enlargement causes symptoms, but larger prostates are more likely to compress the urethra and cause lower urinary tract symptoms (LUTS).
Accurate prostate volume measurement is essential for multiple clinical decisions:
- Diagnosing and staging the severity of BPH
- Calculating PSA density for prostate cancer risk assessment
- Planning surgical procedures such as transurethral resection of the prostate (TURP) or holmium laser enucleation (HoLEP)
- Determining eligibility for minimally invasive therapies like UroLift, Rezลซm, or prostatic artery embolization
- Calculating brachytherapy seed dosing for prostate cancer treatment
- Monitoring response to medical therapy (e.g., 5-alpha-reductase inhibitors)
How is Prostate Volume Measured?
Prostate volume is primarily measured using cross-sectional imaging. The two most common modalities are Transrectal Ultrasound (TRUS), which is the standard for routine clinical practice, and Multiparametric Magnetic Resonance Imaging (mpMRI), which is increasingly used for prostate cancer evaluation and provides the highest anatomical detail.
During the imaging study, the radiologist or sonographer measures three orthogonal dimensions of the gland:
- Length (L): The longest craniocaudal dimension, measured from the base to the apex
- Width (W): The transverse dimension at the mid-gland level
- Height (H): The anteroposterior dimension
These three linear measurements are then applied to a geometric formula to estimate the gland's volume. While MRI planimetry (step-section volumetry), where the gland is manually traced on sequential slices, remains the gold standard for accuracy, it is time-consuming and not routinely used in clinical practice. Mathematical formulas provide a rapid, reproducible estimate suitable for most clinical scenarios, with a typical accuracy within 10-20% of planimetry measurements.
Prostate Volume Calculation Formulas
Two formulas are widely used in clinical urology. The ellipsoid formula (also called the prolate ellipsoid formula) is the most common and is taught in virtually every urology residency program. The "bullet" formula has been proposed as a more anatomically accurate alternative, particularly for smaller glands.
| Formula | Equation | Multiplier | Best Used For |
|---|---|---|---|
| Ellipsoid (Prolate) | L ร W ร H ร (ฯ/6) | 0.52 | Standard clinical use; all prostate sizes |
| Bullet (Cylinder + Hemisphere) | L ร W ร H ร (5ฯ/24) | 0.65 | Prostates smaller than 55 mL |
Source: MacMahon PJ, et al. Modified prostate volume algorithm improves transrectal US volume estimation in men presenting for prostate brachytherapy. Radiology. 2009;250(1):273-280. doi:10.1148/radiol.2501080265
The ellipsoid formula assumes the prostate is shaped like a prolate spheroid, essentially a sphere stretched along one axis. The bullet formula models the prostate as a cylinder capped by a hemisphere at one end, which more closely matches the gland's actual anatomy in smaller volumes. MacMahon et al. demonstrated that the bullet formula reduces systematic underestimation by approximately 20% in glands smaller than 55 mL compared to MRI planimetry.
How to Calculate Prostate Volume: Worked Examples
To illustrate how these formulas are applied in clinical practice, the following examples walk through complete calculations with realistic measurements obtained from a transrectal ultrasound study.
Example 1: Ellipsoid Formula with a Moderately Enlarged Prostate
A 65-year-old man presents with lower urinary tract symptoms. A TRUS examination yields the following measurements:
- Length (L) = 5.2 cm
- Width (W) = 4.1 cm
- Height (H) = 3.8 cm
Step-by-Step Calculation
= 81.016 cmยณ
= 42.42 mL
Example 2: Bullet Formula with the Same Measurements
Using the identical measurements from Example 1, we apply the bullet formula to see how the results differ.
Step-by-Step Calculation
= 53.03 mL
Notice the significant difference: the bullet formula yields a volume approximately 25% higher than the ellipsoid formula for this gland. This discrepancy becomes even more pronounced in smaller prostates, as demonstrated in the next example.
Example 3: Comparing Formulas in a Small Prostate
A 52-year-old man undergoes TRUS with the following measurements:
- Length (L) = 4.0 cm
- Width (W) = 3.5 cm
- Height (H) = 3.0 cm
Step-by-Step Calculation
Bullet: 42.0 ร 0.6545 = 27.49 mL
In this smaller prostate, the bullet formula yields a volume 25% higher than the ellipsoid formula. MacMahon et al. validated this finding against MRI planimetry and concluded that the bullet formula more accurately reflects true gland volume in prostates under 55 mL. For larger glands, the two formulas converge in their estimates.
Example 4: PSA Density Calculation
A 68-year-old man has a serum PSA of 6.8 ng/mL and TRUS measurements of L = 5.0 cm, W = 4.2 cm, H = 3.6 cm. Calculate his PSA density using the ellipsoid volume.
Step-by-Step Calculation
= 75.6 ร 0.5236 = 39.58 mL
= 6.8 รท 39.58
= 0.172 ng/mL/mL
This PSA density of 0.17 ng/mL/mL falls in the borderline range (0.15-0.25), suggesting that the elevated PSA may not be fully explained by benign enlargement alone. According to AUA guidelines, this patient would be a candidate for multiparametric MRI before considering a prostate biopsy.
Prostate Size Classification
Urologists categorize prostate volume into clinical tiers to guide treatment decisions. These thresholds are based on consensus guidelines from the American Urological Association (AUA) and the European Association of Urology (EAU).
| Classification | Volume Range | Clinical Significance |
|---|---|---|
| Normal | < 20 mL | Typical of young adults; no BPH |
| Mild Enlargement | 20 โ 30 mL | Early BPH; often managed with watchful waiting or alpha-blockers |
| Moderate Enlargement | 30 โ 50 mL | Established BPH; medical therapy or minimally invasive options considered |
| Severe Enlargement | > 50 mL | Advanced BPH; surgical intervention often indicated (TURP, HoLEP, etc.) |
Source: Gravas S, et al. EAU Guidelines on Management of Non-Neurogenic Male LUTS. European Association of Urology. 2023 Edition. Available online
It is important to note that prostate volume does not always correlate directly with symptom severity. Some men with moderately enlarged prostates experience severe lower urinary tract symptoms (LUTS), while others with very large glands remain largely asymptomatic. Treatment decisions should always integrate volume with symptom scores (International Prostate Symptom Score, IPSS), uroflowmetry results, post-void residual volume, and patient preferences.
Normal Prostate Volume by Age
Prostate volume increases progressively with age. The most authoritative reference for age-specific prostate volumes comes from a landmark autopsy study by Berry et al. (1984), which remains the gold standard reference cited in urological literature. This study examined 102 prostates from men aged 31 to 100 years and provided detailed volumetric data.
| Age Decade | Median Volume (mL) | Typical Range (mL) |
|---|---|---|
| 31 โ 40 years | ~10 | 7 โ 15 |
| 41 โ 50 years | ~15 | 10 โ 20 |
| 51 โ 60 years | ~20 | 15 โ 30 |
| 61 โ 70 years | ~30 | 20 โ 40 |
| 71 โ 80 years | ~35 | 25 โ 50 |
| 81+ years | ~40 | 30 โ 60+ |
Source: Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. Journal of Urology. 1984;132(3):474-479. doi:10.1016/S0022-5347(17)49698-4
These values represent median volumes from a healthy population. Individual variation is substantial, and factors such as genetics, body mass index, metabolic syndrome, and hormonal status can all influence prostate growth. Men with volumes significantly above the expected range for their age should be evaluated for BPH and, if indicated, prostate cancer.
What is PSA Density and Why Does it Matter?
PSA Density (PSAD) is a calculated value that relates a patient's serum Prostate-Specific Antigen (PSA) level to the volume of the prostate gland. It is computed as:
PSA Density = Total PSA (ng/mL) รท Prostate Volume (mL)
PSA is produced by both benign and malignant prostate tissue. Larger prostates naturally produce more PSA, which can elevate serum levels independently of cancer. A man with a 60 mL prostate may have a PSA of 6 ng/mL purely due to his gland size, while the same PSA in a man with a 20 mL prostate would be far more concerning. PSA density helps clinicians distinguish between PSA elevation caused by BPH versus that potentially caused by prostate cancer.
PSA Density Interpretation Thresholds
The clinical utility of PSA density was established by Benson et al. (1992) and has since been incorporated into major urological guidelines, including the AUA Guidelines on Prostate Cancer Early Detection.
| PSA Density | Risk Category | Clinical Recommendation |
|---|---|---|
| < 0.15 ng/mL/mL | Low Risk | PSA elevation likely due to BPH; routine monitoring |
| 0.15 โ 0.25 ng/mL/mL | Intermediate Risk | Consider multiparametric MRI before biopsy |
| > 0.25 ng/mL/mL | High Risk | Strongly consider prostate biopsy; higher probability of clinically significant cancer |
Source: Benson MC, et al. The role of PSA density in needle biopsy pathologic outcomes. Cancer. 1992;69(8):2101-2105; and AUA Guidelines on Early Detection of Prostate Cancer, 2024.
A PSA density greater than 0.15 ng/mL/mL is widely considered the threshold for further investigation. In men with enlarged prostates and borderline PSA levels (4-10 ng/mL, the so-called "gray zone"), PSA density significantly improves the specificity of cancer detection compared to PSA alone. Studies have shown that using a PSAD cutoff of 0.15 can reduce unnecessary biopsies by 20-30% while maintaining high sensitivity for clinically significant cancers.
Limitations of PSA Density
While PSA density is a valuable adjunct to PSA testing, it has important limitations. PSA levels can be temporarily elevated by prostatitis, urinary tract infection, recent ejaculation, vigorous cycling, or digital rectal examination. Medications such as 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce both PSA and prostate volume, complicating PSAD interpretation. In men taking these medications, the measured PSA should be doubled before calculating PSA density. Additionally, PSA density is less reliable in very small prostates (< 15 mL) where measurement errors have a proportionally larger impact.
Clinical Applications of Prostate Volume
Beyond cancer risk assessment, prostate volume measurement plays a critical role in treatment planning across multiple urological conditions.
Surgical Planning
The choice of surgical procedure for BPH is heavily influenced by prostate volume. Traditional TURP is most effective for glands between 30 and 80 mL. For very large glands (> 80-100 mL), holmium laser enucleation (HoLEP) or simple prostatectomy is preferred. Open prostatectomy, once the standard for large glands, has been largely replaced by these minimally invasive techniques.
Minimally Invasive Therapies
Novel treatments such as UroLift (prostatic urethral lift) are typically indicated for prostates between 20 and 100 mL, with optimal results in glands under 70 mL. Rezลซm (water vapor thermal therapy) is effective for glands up to approximately 80 mL. Prostatic artery embolization (PAE) can be performed on glands of virtually any size but shows the best outcomes in moderately enlarged glands (40-100 mL).
Brachytherapy
For prostate cancer patients undergoing brachytherapy (radioactive seed implantation), precise prostate volume measurement is essential. The number and activity of seeds required are calculated based on gland volume. An underestimation of volume can lead to underdosing and treatment failure, while overestimation can result in excessive radiation exposure to surrounding tissues.
Medical Therapy Monitoring
5-alpha-reductase inhibitors (finasteride, dutasteride) reduce prostate volume by approximately 20-30% over 6-12 months of continuous use. Serial volume measurements allow clinicians to objectively assess treatment response. A failure of the gland to shrink after 12 months of therapy may indicate poor compliance or the need for alternative treatment.
Frequently Asked Questions
What is the normal prostate size by age?
Prostate volume increases progressively with age. According to the landmark autopsy study by Berry et al. (1984), median prostate volume is approximately 10 mL in men aged 31-40, 20 mL in men aged 51-60, and 30 mL in men aged 61-70. See the age-specific reference table above for detailed values by decade.
Does a larger prostate volume mean I have prostate cancer?
No. Prostate enlargement is most commonly caused by Benign Prostatic Hyperplasia (BPH), a non-cancerous condition affecting the majority of aging men. Prostate volume alone does not diagnose cancer. However, a high PSA density (PSA relative to volume) can indicate increased cancer risk and may warrant further investigation with multiparametric MRI or biopsy.
How accurate is the ellipsoid formula compared to MRI planimetry?
The ellipsoid formula is the clinical standard but tends to underestimate true prostate volume by approximately 10-20% compared to MRI planimetry (step-section volumetry), which remains the gold standard. The bullet formula (L ร W ร H ร 5ฯ/24) reduces this underestimation, particularly in glands smaller than 55 mL, as demonstrated by MacMahon et al. (2009). For routine clinical use, either formula provides a sufficiently accurate estimate.
Can prostate volume decrease?
Yes. Medications called 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) can reduce prostate volume by approximately 20-30% over 6-12 months of continuous use. These drugs work by blocking the conversion of testosterone to dihydrotestosterone (DHT), the primary hormone driving prostate growth. These medications also reduce PSA levels by about 50%, which must be accounted for when interpreting PSA results and calculating PSA density.
Why do I need to know my prostate volume before a biopsy or surgery?
Prostate volume is critical for multiple clinical decisions. It determines eligibility for certain minimally invasive procedures (e.g., UroLift is typically recommended for glands under 100 mL). It is essential for calculating brachytherapy seed dosing in prostate cancer treatment. It also allows accurate interpretation of PSA through PSA density calculation, improving cancer detection specificity and helping to avoid unnecessary biopsies.
What is the difference between mL and cc for prostate volume?
There is no difference. One milliliter (mL) is exactly equal to one cubic centimeter (cc). The terms are interchangeable in medical practice. This calculator allows you to display results in either unit according to your preference or institutional convention.
How often should prostate volume be measured?
There is no universal recommendation for routine volume measurement in asymptomatic men. Volume is typically measured when clinically indicated, such as when PSA is elevated, when symptoms of BPH develop, or when planning treatment. In men being monitored with active surveillance for low-risk prostate cancer, volume may be measured annually alongside PSA and digital rectal examination.
Sources and References
The formulas, classifications, and clinical thresholds used in this calculator are based on peer-reviewed medical literature and established guidelines from leading urological organizations:
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. Journal of Urology. 1984;132(3):474-479. View study
- MacMahon PJ, Kennedy A-M, Murphy DT, et al. Modified prostate volume algorithm improves transrectal US volume estimation in men presenting for prostate brachytherapy. Radiology. 2009;250(1):273-280. View study
- Benson MC, et al. The role of PSA density in needle biopsy pathologic outcomes. Cancer. 1992;69(8):2101-2105.
- American Urological Association (AUA). Guidelines on Early Detection of Prostate Cancer, 2024. View guidelines
- European Association of Urology (EAU). Guidelines on Management of Non-Neurogenic Male LUTS, 2023 Edition. View guidelines